One-glance verdict
Not enough data
Fair value unavailable
Not enough cash-flow history to value this one with our method.
Fundamentals snapshot
Enlivex Ltd.
ENLV · NCM · Healthcare · Biotechnology
Current price
$0.20
52-week range
$0.20 - $27.15
Market cap
$4.08M
Balance sheet
Distressed
-19.26x Concerning
Net debt $12.03M. Interest coverage shows how many times profit covers the interest bill.
What stands out
1 Reward
0 Risks
1 rewards · 0 risks
View details ↓What this company does
Enlivex Ltd.
Enlivex Ltd. is a company in Israel developing a new type of treatment called Allocetra, which aims to help the body's own cells fight diseases. Their main focus is on therapies that are still in testing stages, meaning they are not yet approved for widespread use and haven't generated significant sales yet. This matters because investors are betting on the potential success of these experimental treatments to drive future growth.
How the company got here
Enlivex Ltd. was founded in 2005 and was formerly known as Enlivex Therapeutics Ltd. before changing its name in February 2026. The company is a clinical-stage immunotherapy firm based in Israel. It has focused on developing a novel class of therapies that reprogram macrophages, a type of immune cell. This approach aims to restore balance to the immune system, particularly in conditions where it's overactive or unbalanced. The company's journey has involved advancing its lead therapy, Allocetra™, through various clinical trials for different conditions.
What it actually does
Enlivex is a biotechnology company focused on developing a cell therapy called Allocetra™. This therapy is designed to reprogram macrophages, which are immune cells that play a crucial role in the body's defense and inflammatory responses. By reprogramming these cells, Enlivex aims to restore a healthy balance to the immune system, addressing conditions where the immune response is either too strong or not functioning correctly. The company is advancing Allocetra™ through clinical trials for various medical conditions.
Allocetra™ for Osteoarthritis
Enlivex is developing Allocetra™ as an intra-articular injection, meaning it's injected directly into a joint, to treat osteoarthritis. Osteoarthritis is a condition where the cartilage in joints wears down, causing pain and stiffness, and it's the most common form of arthritis. The company is testing this treatment for knee osteoarthritis in Phase 1/2 trials and also for osteoarthritis in the temporomandibular joint (TMJ), which is the joint connecting your jawbone to your skull. This business line targets patients suffering from joint pain and reduced mobility due to cartilage degeneration.
Allocetra-OTS for Sepsis
Another application for Enlivex's technology is Allocetra-OTS, a therapy being developed for adult sepsis patients experiencing organ failure. Sepsis is a life-threatening condition where the body's response to infection causes widespread inflammation and can lead to organ damage. Allocetra-OTS is designed to help manage this severe immune response. This program is currently in Phase 2 clinical trials, indicating it's further along in testing its effectiveness and safety for this critical condition.
Treasury Strategy: RAIN Protocol
In addition to its drug development efforts, Enlivex has established a unique treasury strategy centered around the RAIN protocol, a decentralized prediction markets infrastructure. A portion of the fees generated by the RAIN protocol is used to buy back and burn RAIN tokens, which can create deflationary pressure on the token. Enlivex is the first publicly listed company to adopt this type of treasury structure, aiming to generate value through its involvement in the prediction markets ecosystem alongside its core biotech business.
Price history
How the share price has moved
—
Loading price history…
Earnings history
Last 8 quarters — what happened
Click any quarter to read the call summary and what the numbers say.
FY2024 Q4
$-13.11M
FY2025 Q4
$-10.48M
Revenue
—
Net income
$1.24B
Diluted EPS
25.48
Operating cash flow
$-10.42M
Free cash flow
$-10.48M
Fetching…
Sources
Revenue
—
Net income
$-15.01M
Diluted EPS
-0.73
Operating cash flow
$-13.01M
Free cash flow
$-13.11M
Fetching…
Sources
Is it cheap or expensive?
Fair value — vs current price $0.20
We couldn't calculate a fair value right now.
Is it drowning in debt?
Distressed
Net debt $12.0M. Interest coverage -19.3x.
Net debt
$12.03M
Interest coverage
-19.26x
Enlivex Ltd.'s profit covers its interest bill about 0.0 times over. which is weaker than most peers shown here and 4 peers sit below 1x, which is the danger zone where profit does not fully cover the interest bill.
Distressed
Worse cushion
Baseline
Better cushion
ENLV
BASELINE
Enlivex Ltd.
Total debt $17.54M Interest coverage -19.26x This is the baseline the peer rows are being compared against.
Total debt — Interest coverage -48.18x Neither company has much profit cushion over interest right now.
Total debt $5.05M Interest coverage -15.67x Neither company has much profit cushion over interest right now.
Total debt $22.29M Interest coverage -68.14x Neither company has much profit cushion over interest right now.
Total debt $1.34M Interest coverage -4,509.50x Neither company has much profit cushion over interest right now.
What you should know
The case for and against ENLV
1 Reward
0 Risks
Rewards
-
Returns 162.9% on equity, ahead of 75% of its peers.
Risks
The numbers
All the key metrics, grouped by purpose
Tap any ? icon to learn what it means.
Valuation
How expensive the stock looks
P/E (TTM)
0.00x
Forward P/E
-0.26x
P/B
0.00x
P/S
—
EV/EBITDA
-0.66x
PEG ratio
—
Profitability
How much profit each dollar creates
Gross margin
0.0%
Operating margin
0.0%
Net margin
0.0%
ROE
162.9%
ROA
-0.6%
Health
Liquidity and balance-sheet strength
Debt / equity
0.00x
Current ratio
119.39x
Quick ratio
0.18x
Total debt
$17.54M
Total cash
$5.52M
Growth
How the business has been compounding
Revenue TTM
$0.00
Revenue 5Y CAGR
—
EPS TTM
494.00
EPS 5Y CAGR
—
Cash flow
How much cash the business throws off
Operating CF TTM
$-70.90M
Free CF TTM
$-10.48M
FCF margin
—
Dividend
Shareholder payout
Yield
0.0%
Payout ratio
0.0%
Last ex-div date
—